Back to Search Start Over

Identification of biomarkers for drug-resistant endometriosis using clinical proteomics.

Authors :
Kobayashi, Yoichi
Fukutomi, Toshiyuki
Mita, Shizuka
Watanabe, Momoe
Suzuki, Atsushi
Source :
Human Cell; Mar2021, Vol. 34 Issue 2, p394-399, 6p
Publication Year :
2021

Abstract

Dienogest (DNG), is an effective and widely used progestin used in the treatment of endometriosis, yet clinically, a subset of cases show resistance to DNG treatment. During a previous investigation on the effect of DNG of cytokines and growth factor production, we incidentally found that endometriotic cyst fluid did not demonstrate inhibitory effects to DNG in a subset of cases. To clarify the mechanisms of this resistance to DNG, we performed proteomics analysis to compare the protein expression between DNG-sensitive and resistant cases. Based upon our results, several proteins were extracted that relate to neutrophil granulocyte activation marker (myeloperoxidase, lactotransferrin), inflammation (azurocidin, neutrophil gelatinase-associated lipocalin, etc.), and others biological processes reflecting the clinical environment of the endometriotic cyst. Among these proteins, azurocidin (AZU) is perhaps most interesting one as azurocidin is a protease that cleaves insulin-like growth factor-1 (IGFBP-1) associated with clear cell carcinoma of the ovary. We propose that the proteins extracted in the present study warrant further investigation in their relationship to carcinogenesis of endometrioma. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09147470
Volume :
34
Issue :
2
Database :
Complementary Index
Journal :
Human Cell
Publication Type :
Academic Journal
Accession number :
148887320
Full Text :
https://doi.org/10.1007/s13577-020-00465-0